Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 4512 | 1.29 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 100.5M | 6.5x | --- |
Spero Therapeutics Inc | 74.0M | 3.2x | --- |
2Seventy Bio Inc | 191.2M | -0.9x | --- |
G1 Therapeutics Inc | 129.7M | -2.6x | --- |
Rigel Pharmaceuticals Inc | 166.6M | -8.7x | --- |
Fortress Biotech Inc | 35.3M | -0.3x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $100.5M |
---|---|
Revenue (TTM) | $119.2M |
Shares Outstanding | 77.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.06 |
EPS | $0.20 |
Book Value | $-0.70 |
P/E Ratio | 6.5x |
Price/Sales (TTM) | 0.8 |
Price/Cash Flow (TTM) | 5.4x |
Operating Margin | 9.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.